Onward Therapeutics Secures $28 Million for Oncology Advancements in Taiwan

Onward Therapeutics Secures $28 Million for Oncology Advancements in Taiwan



In a significant step towards enhancing its oncology pipeline, Onward Therapeutics, Inc. has announced the successful closure of its Series B financing, amassing NT$900 million (approximately US$28 million). This financing round, which was executed across two phases, is particularly notable as it marks the company's first capital increase since relocating its global headquarters to Taiwan in October 2025.

Dr. C. Grace Yeh, Chairperson and CEO of Onward Therapeutics, expressed gratitude towards existing shareholders while welcoming new investors who have joined the company in this funding round. "This financing allows us to advance our clinical programs while establishing our research and development (R&D) presence here in Taiwan. Many patients suffering from difficult-to-treat or relapsed cancers are still facing limited options. Our objective is to provide them with new therapeutic avenues," remarked Dr. Yeh.

The Series B funding will be allocated towards several key initiatives. This includes the acceleration of clinical programs, the manufacturing of clinical supplies, and investments in early-stage research and development. Continuing on from previous funding rounds, where Onward Therapeutics raised approximately CHF 75.5 million (around US$90 million), this recent success demonstrates the robust support from both individual and institutional investors. Notable participants in this financing round include CDIB Capital Healthcare Ventures and Hong Kong Chlitina International, alongside several new institutional investors such as Beiley Biofund and Hercules Bioventure Partners.

Onward Therapeutics’ portfolio boasts two advanced clinical-stage programs: OT-A201, a bispecific antibody designed to combat tumor immune evasion, and OT-C001, a pioneering allogeneic natural killer (NK) cell therapy derived from umbilical cord blood. OT-A201 is in Phase 1b trials, while OT-C001 is being evaluated in France for patients with diffuse large B-cell lymphoma (DLBCL) who have either relapsed from or are refractory to previous therapies. Preliminary results from these trials indicate promising safety profiles and significant clinical activity, prompting further investigations.

Moreover, the company is nurturing early-stage drug discovery projects focusing on onco-metabolism and tumor-associated antigens, emphasizing its commitment to innovation in the oncology space.

Dr. Armand de Gramont, Co-founder and President of R&D at Onward, highlighted the core vision of the company: "We strive to translate innovative scientific discoveries into meaningful clinical outcomes. By focusing on therapeutic indications where our treatments can significantly address resistance, we are committed to developing an exceptional oncology pipeline that will provide novel treatment options for patients."

Looking forward, Onward Therapeutics is not only aiming for growth but also plans to register on the Taipei Exchange's Emerging Stock Board by the end of 2027. This strategic move will further boost its local R&D capabilities while expanding its clinical trials in Taiwan, thereby solidifying its position in the global oncology landscape.

Founded in November 2019, Onward Therapeutics is driven by its mission to combat cancer drug resistance through innovative and diversified therapeutic options. Headquartered in Taipei, Taiwan, with additional teams located in Switzerland and France, the company is dedicated to transforming the treatment paradigm for patients with hard-to-treat cancers. For more information visit www.onward-therapeutics.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.